FdaApplication
NDA 208944
Identifiers
- fda_app_no: NDA208944
Properties
| Property | Value |
|---|---|
| applicant_name | SUPERNUS PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2017-08-24 |
Revenue by product
GOCOVRI
| Period | Revenue |
|---|---|
| Q2 2026 | $37.5M |
| Q1 2026 | $35.2M |
| Q4 2025 | $38.6M |
| Q3 2025 | $40.8M |
| Q2 2025 | $36.7M |
| Q1 2025 | $30.7M |
| Q4 2024 | $36.9M |
| Q3 2024 | $35.7M |
| Q2 2024 | $31.7M |
| Q1 2024 | $26.6M |
| Q4 2023 | $32.0M |
| Q3 2023 | $32.9M |
| Q2 2023 | $28.8M |
| Q1 2023 | $26.0M |
| Q4 2022 | $29.2M |
| Q3 2022 | $27.9M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| GOCOVRI | AMANTADINE HYDROCHLORIDE | EQ 68.5MG BASE | CAPSULE, EXTENDED RELEASE;ORAL |
| GOCOVRI | AMANTADINE HYDROCHLORIDE | EQ 137MG BASE | CAPSULE, EXTENDED RELEASE;ORAL |
2 products